Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Sacubitril/Valsartan and Ivabradine in Heart Failure-Reference-Cited by-同舟云学术

Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Sacubitril/Valsartan and Ivabradine in Heart Failure

Published:2020-03-01 Issue:3 Volume:5 Page:336
ISSN:2380-6583
Container-title:JAMA Cardiology
language:en
Short-container-title:JAMA Cardiol

Author:

Sumarsono Andrew¹,Vaduganathan Muthiah²,Ajufo Ezimamaka¹,Navar Ann Marie³⁴,Fonarow Gregg C.⁴⁵,Das Sandeep R.⁶,Pandey Ambarish⁶

Affiliation:

1. Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas

2. Brigham and Women’s Heart and Vascular Center and Hospital, Harvard Medical School, Boston, Massachusetts

3. Duke Clinical Research Institute, Durham, North Carolina

4. Associate Editor, JAMA Cardiology

5. Ahmanson–University of California, Los Angeles Cardiomyopathy Center, University of California Los Angeles Medical Center

6. Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas

Publisher

American Medical Association (AMA)

Subject

Cardiology and Cardiovascular Medicine

Link

https://jamanetwork.com/journals/jamacardiology/articlepdf/2755871/jamacardiology_sumarsono_2019_br_190021_1609877294.89407.pdf

Reference15 articles.

1. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.;Yancy;Circulation,2016

2. Early adoption of sacubitril/valsartan for patients with heart failure with reduced ejection fraction: insights from Get With the Guidelines–Heart Failure (GWTG-HF).;Luo;JACC Heart Fail,2017

3. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry.;Greene;J Am Coll Cardiol,2018

4. Patient, provider, and practice characteristics associated with sacubitril/valsartan use in the United States.;DeVore;Circ Heart Fail,2018

5. Use of aldosterone antagonists in heart failure.;Albert;JAMA,2009

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of a systematic approach for implementing novel medications in clinical practice: an observational study with dapagliflozin;European Journal of Clinical Pharmacology;2024-06-10

2. Optimizing outcomes in heart failure: 2022 and beyond;ESC Heart Failure;2023-04-14

3. Heart Failure Duration and Mechanistic Efficacy of Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction;Journal of Cardiac Failure;2022-12

4. Effects of sacubitril-valsartan on heart failure patients with mid-range ejection fractions: A systematic review and meta-analysis;Frontiers in Pharmacology;2022-10-24

5. Relation of Household Income to Access and Adherence to Combination Sacubitril/Valsartan in Heart Failure: A Retrospective Analysis of Commercially Insured Patients;Circulation: Cardiovascular Quality and Outcomes;2022-07